6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Originaltext

Diese Übersetzung bewerten

Mit deinem Feedback können wir Google Übersetzer weiter verbessern

Latest Press Releases

Time	Headline
7m ago	Yapi ve Kredi Bankasi : Successful issuance of 500 million US$ perpetual Additional Tier 1 Capital Transaction
12m ago	Crown Castle Names Kris Hinson as Chief Commercial Officer and Mark Lennon as Chief Information Officer
17m ago	Hovnanian Enterprises Reports Fiscal 2026 Second Quarter Results
17m ago	LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
17m ago	KKR Sells CIRCOR Aerospace to Parker Hannifin for $2.55 Billion

About

3.13USD+0.00 +0.00%

Closed • Updated at 13:33 GMT+00:00

Market Cap$805.76M

Volume7.81M

Beta2.71

RSI71.97

Gross Margin68.38%

Health TechnologyPharmaceuticals: Major

Esperion Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Esperion to be Acquired by ARCHIMED

Esperion to Report First Quarter 2026 Financial Results on May 7

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Community Chat

Ask AI